Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Change In Receivables : HK$0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Change In Receivables?

Biocytogen Pharmaceuticals (Beijing) Co's change in receivables for the quarter that ended in Dec. 2024 was HK$0 Mil. It means Biocytogen Pharmaceuticals (Beijing) Co's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

Biocytogen Pharmaceuticals (Beijing) Co's change in receivables for the fiscal year that ended in Dec. 2024 was HK$-103 Mil. It means Biocytogen Pharmaceuticals (Beijing) Co's Accounts Receivable increased by HK$103 Mil from Dec. 2023 to Dec. 2024 .

Biocytogen Pharmaceuticals (Beijing) Co's Accounts Receivable for the quarter that ended in Dec. 2024 was HK$245 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Biocytogen Pharmaceuticals (Beijing) Co's Days Sales Outstanding for the six months ended in Dec. 2024 was 73.47.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biocytogen Pharmaceuticals (Beijing) Co's liquidation value for the six months ended in Dec. 2024 was HK$-1,037 Mil.

Biocytogen Pharmaceuticals (Beijing) Co Change In Receivables Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Change In Receivables Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

-38.39

-43.91

-5.13

-42.67

-103.22

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial				-	-	-	-	-

Biocytogen Pharmaceuticals (Beijing) Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biocytogen Pharmaceuticals (Beijing) Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	244.975	/	608.525	*	91
=	73.47

2. In Ben Graham's calculation of liquidation value, Biocytogen Pharmaceuticals (Beijing) Co's accounts receivable are only considered to be worth 75% of book value:

Biocytogen Pharmaceuticals (Beijing) Co's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	406.977	-	1683.412	+	0.75 * 244.975	+	0.5 * 110.565
=	-1,037

Biocytogen Pharmaceuticals (Beijing) Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Executives

Wei Ke Xiang Gang Jing Mao You Xian Gong Si	2101 Beneficial owner
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines